Q-omics provides the consensus-scored SRRT profile across patient tissues and cancer cell-line models. SRRT expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SRRT is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, SRRT protein abundance shows 36,048 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where SRRT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRRT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRRT survival associations across molecular data types. SRRT RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRRT RNA expression–survival associations across cancer types. High SRRT expression shows unfavorable associations in UVM, KICH, ACC, LIHC, KIRC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SRRT RNA expression.
This table summarizes SRRT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SRRT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRRT shows higher tumor expression in COAD, HNSC, STAD, LIHC, LUSC and LUAD. The COAD box plot shows higher SRRT RNA expression in tumor versus normal tissue (log2 FC = +0.946, t-test p < 0.001).
This table shows molecular features associated with SRRT in patient tissues and cancer cell lines. In patient samples, SRRT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRRT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
